Home » Medical » Dr. Mark Holterman: A Multifaceted Man of Medicine

Dr. Mark Holterman: A Multifaceted Man of Medicine

When thinking of doctors it is easy to think of the perks, the nice house, generous salary, and respect that come with being a doctor. Dr. Mark Holterman certainly is a well-respected physician, graduating from Yale University with a major in biology and earning both a Ph.D. and an MD from the University of Virginia. He has a wide presence in several medicine-related organizations and is well respected as a pediatric surgeon. However, as a doctor, he goes above and beyond the normal demands of the white coat.


In previous positions, he was the surgeon-in-chief at Advocate Christ Children’s Hospital as well as Attending Pediatric Surgeon at Rush University Medical Center. He still holds regular classes at the University of Illinois College of Medicine where he has been a member of teaching staff for 10 years while continuing to practice. He also has taken on the position of CEO of Mariam Global Health, an investment firm providing a crucial foundation to science and health technology researchers as they bring their advancements to a global market. This is a prime example of a multifaceted, dutiful health provider!


But at the end of the day, a doctor’s job is saving and improving lives (https://www.behance.net/MarkJHolterman). On and off duty, Dr. Mark Holterman gives back to his patients and to the community, setting him apart from other colleagues and bringing him lasting recognition. An avid volunteer advocate, he is known for his support of many charities, including International Pediatric Specialists Alliance for the Children of Vietnam, which provides training and support to Vietnam professionals. He played a key role in the founding of the Hannah Sunshine Foundation, a developer of cutting-edge restorative treatments for children with rare diseases, while still actively practicing in the state of Illinois (Doctors.HealtGrove). With over 29 years of experience, Dr. Mark Holterman uses the latest in treatments to save arguably the most vulnerable population of patients, the nation’s children.